RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
RAPT Therapeutics has appointed Lori Lyons-Williams as the new chair of its board of directors, effective January 3, 2025. She succeeds William Rieflin, who will remain as a consultant. Lori has been a board member for four years and brings over 20 years of experience in the biotech and pharmaceutical industries. She is currently the President and CEO of Abdera Therapeutics and has held significant roles at Neumora Therapeutics, Dermira, and Allergan. Her expertise includes the successful launch of multiple commercial products, including BOTOX®. Brian Wong, President and CEO of RAPT, expressed confidence in Lori's ability to guide the company through late-stage development and commercialization efforts, particularly in the field of inflammatory diseases. William Rieflin, who led the board for nine years, expressed his confidence in the board and management team under Lori's leadership.
RAPT Therapeutics ha nominato Lori Lyons-Williams come nuovo presidente del consiglio di amministrazione, con effetto dal 3 gennaio 2025. Succede a William Rieflin, che rimarrà come consulente. Lori è stata membro del consiglio per quattro anni e porta con sé oltre 20 anni di esperienza nelle industrie biotecnologiche e farmaceutiche. Attualmente è Presidente e CEO di Abdera Therapeutics e ha ricoperto ruoli significativi in Neumora Therapeutics, Dermira e Allergan. La sua esperienza include il lancio di più prodotti commerciali, tra cui BOTOX®. Brian Wong, Presidente e CEO di RAPT, ha espresso fiducia nella capacità di Lori di guidare l'azienda attraverso gli sviluppi avanzati e gli sforzi di commercializzazione, in particolare nel campo delle malattie infiammatorie. William Rieflin, che ha guidato il consiglio per nove anni, ha espresso la propria fiducia nel consiglio e nel team di gestione sotto la guida di Lori.
RAPT Therapeutics ha nombrado a Lori Lyons-Williams como la nueva presidenta de su consejo de administración, con efecto a partir del 3 de enero de 2025. Ella sucede a William Rieflin, quien permanecerá como consultor. Lori ha sido miembro del consejo durante cuatro años y aporta más de 20 años de experiencia en las industrias biotecnológica y farmacéutica. Actualmente, es Presidenta y CEO de Abdera Therapeutics y ha ocupado roles significativos en Neumora Therapeutics, Dermira y Allergan. Su experiencia incluye el lanzamiento exitoso de múltiples productos comerciales, incluido BOTOX®. Brian Wong, Presidente y CEO de RAPT, expresó confianza en la capacidad de Lori para guiar a la empresa a través del desarrollo en fases avanzadas y los esfuerzos de comercialización, particularmente en el campo de las enfermedades inflamatorias. William Rieflin, quien lideró el consejo durante nueve años, expresó su confianza en el consejo y en el equipo de gestión bajo el liderazgo de Lori.
RAPT Therapeutics는 Lori Lyons-Williams를 이사회의 새로운 의장으로 임명하였습니다. 이는 2025년 1월 3일부터 시행됩니다. 그녀는 William Rieflin을 이어 임명되며, Rieflin은 컨설턴트로 남아 있을 것입니다. Lori는 4년간 이사로 활동해 왔으며, 생명공학 및 제약 산업에서 20년 이상의 경험을 보유하고 있습니다. 현재 Abdera Therapeutics의 사장兼 CEO이며, Neumora Therapeutics, Dermira, Allergan에서 중요한 역할을 해왔습니다. 그녀의 전문성에는 BOTOX®를 포함한 여러 상업 제품의 성공적인 출시가 포함됩니다. RAPT의 사장이자 CEO인 Brian Wong은 Lori가 회사의 후기 단계 개발 및 상업화 노력을 이끌어갈 수 있는 능력에 대해 자신감을 표명하였습니다. 9년간 이사회 의장을 맡았던 William Rieflin은 Lori의 리더십 아래 이사회와 경영팀에 대한 신뢰를 나타냈습니다.
RAPT Therapeutics a nommé Lori Lyons-Williams en tant que nouvelle présidente de son conseil d'administration, à compter du 3 janvier 2025. Elle succède à William Rieflin, qui restera consultant. Lori a été membre du conseil pendant quatre ans et apporte plus de 20 ans d'expérience dans les secteurs de la biotechnologie et de la pharmacie. Elle est actuellement présidente et CEO de Abdera Therapeutics et a occupé des postes significatifs chez Neumora Therapeutics, Dermira et Allergan. Son expertise comprend le lancement réussi de plusieurs produits commerciaux, notamment BOTOX®. Brian Wong, président et CEO de RAPT, a exprimé sa confiance dans la capacité de Lori à guider l'entreprise à travers le développement en phases avancées et les efforts de commercialisation, en particulier dans le domaine des maladies inflammatoires. William Rieflin, qui a dirigé le conseil pendant neuf ans, a exprimé sa confiance dans le conseil et l'équipe de direction sous la direction de Lori.
RAPT Therapeutics hat Lori Lyons-Williams zur neuen Vorsitzenden des Vorstandes ernannt, mit Wirkung zum 3. Januar 2025. Sie folgt auf William Rieflin, der als Berater bleibt. Lori ist seit vier Jahren Mitglied des Vorstands und bringt über 20 Jahre Erfahrung in der Biotechnologie- und Pharmaindustrie mit. Derzeit ist sie Präsidentin und CEO von Abdera Therapeutics und hatte bedeutende Positionen bei Neumora Therapeutics, Dermira und Allergan. Ihre Expertise umfasst die erfolgreiche Markteinführung mehrerer kommerzieller Produkte, darunter BOTOX®. Brian Wong, Präsident und CEO von RAPT, äußerte Vertrauen in Loris Fähigkeit, das Unternehmen durch die späten Entwicklungsphasen und die Commercialisierungsbemühungen, insbesondere im Bereich der Entzündungskrankheiten, zu leiten. William Rieflin, der den Vorstand neun Jahre lang geleitet hat, äußerte sein Vertrauen in den Vorstand und das Managementteam unter Loris Führung.
- Appointment of Lori Lyons-Williams as chair, bringing over 20 years of industry experience.
- Lori's past success in launching commercial products, including BOTOX®.
- Continued involvement of William Rieflin as a consultant.
- Transition in leadership could bring uncertainty regarding strategic direction.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company.
“We are pleased to welcome Lori as chair of the board,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “In the four years that Lori has served as a board member, she has provided invaluable guidance based on her leadership experience driving strategic and commercial success in both biotech and pharmaceutical companies. We look forward to her increased involvement as we pursue late-stage development and potential commercialization in the field of inflammatory diseases. We also thank Bill for his nine years on our board providing steady and wise counsel.”
“It has been an honor and a pleasure to serve as chair of the RAPT board,” said Mr. Rieflin. “I have confidence in the board and the management team and believe that Lori has the skills and experience to help guide RAPT into the future.”
Ms. Lyons-Williams, an industry veteran with more than 20 years of experience spanning multinational pharmaceutical and emerging biotech companies, is President and CEO of Abdera Therapeutics, a biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Previously, Lori was president and chief operating officer of Neumora Therapeutics and earlier served as chief commercial officer of Dermira, a biopharmaceutical company focused on immunology and medical dermatology, until its acquisition by Eli Lilly. Before that, she spent 15 years at Allergan in roles of increasing responsibility, where she successfully launched numerous commercial products, including multiple indications of BOTOX®. Lori currently serves on the boards of directors of Abdera Therapeutics and Contineum Therapeutics (Nasdaq: CTNM); she joined the RAPT board of directors in 2021.
“I am excited to partner with Brian and his team as RAPT evolves as a company. I am particularly encouraged by the broad opportunity for RPT904 in food allergy and other allergic diseases as well as the promise and potential of the company’s CCR4-targeted drug candidates,” said Ms. Lyons-Williams. “I look forward to collaborating with my fellow board members as we continue to advance the company.”
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the clinical development of RPT904, the commercial prospects of RPT904 and other statements that are not historical fact. Factors that may cause actual results to differ materially from the plans, intentions and expectations disclosed in these forward-looking statements include uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of RAPT’s product candidates; the risk that clinical trials may have unsatisfactory outcomes; risks associated with preclinical development of product candidates; risks that efforts to secure licensing and other business development opportunities may not be successful; and other important factors, detailed in RAPT’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.
Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
FAQ
Who is the new chair of the RAPT Therapeutics board of directors?
What experience does Lori Lyons-Williams bring to RAPT Therapeutics?
What impact could the appointment of Lori Lyons-Williams have on RAPT Therapeutics?
What role will William Rieflin play after stepping down as chair of RAPT Therapeutics?
What are the potential benefits of Lori Lyons-Williams' previous experience for RAPT Therapeutics?
What are the key areas of focus for RAPT Therapeutics under Lori Lyons-Williams' leadership?
